GDC-0349 is a potent small molecule mTOR inhibitor with Ki of 3.8 nM. GDC-0349 inhibits downstream markers of mTOR, including phospho-4EBP1 and phospho-Akt(S473) in an in vivo PK/PD study in mouse, consistent with an inhibition of both mTORC1 and mTORC2 complexes. GDC-0349 inhibits tumor growth in a dose-dependent manner when dosed orally once daily in athymic mice in a MCF7-neo/Her2 tumor xenograft model. GDC-0349 is also efficacious in other xenograft models, including PC3 (PTEN null) and 786-O (VHL mutant). GDC-0349 is currently in a Phase I clinical trials in the treatment with solid tumors or Non-Hodgkin's lymphoma.
Cell Experiment | |
---|---|
Cell lines | |
Preparation method | Compound activity is tested in 10 point dose curves starting at the highest final concentration of 10 uM. They are serially diluted in 100% DMSO prior to further dilution with assay buffer. The reaction mixture (8 uls) containing 0.25 nM mTOR+GBL enzyme, 400 nM GFP-4E-BP1, 8 uM ATP, 50 mM Hepes pH 7.5, 0.01% Tween 20, 10 mM MnCl2, 1 mM EGTA, 1 mM DTT, 1% DMSO (+/- compound) is incubated at room temperature for 30 minutes. 8 uL of solution containing 2 nM Tb-anti-p4E-BP1 antibody & 10 mM EDTA diluted TR-FRET buffer is then added and incubated for 30 minutes to stop the reaction. The plate is scanned with the Envision plate reader. Ki values are calculated in Assay Explorer using the Morrison ATP-competitive tight binding equation for Ki apparent determination. |
Concentrations | |
Incubation time |
Animal Experiment | |
---|---|
Animal models | MCF7-neo/Her-2 mouse xenograft breast cancer model |
Formulation | 0.5% methylcellulose/0.2% Tween 80 (MCT) |
Dosages | 10, 20, 30, 40, 50, 60, 70, and 80 mg/kg QD for 24 days |
Administration | orally |
Molecular Weight | 452.55 |
Formula | C24H32N6O3 |
CAS Number | 1207360-89-1 |
Solubility (25°C) | DMSO 90 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related mTOR Products |
---|
Thioether-cyclized helix B peptide, CHBP
Thioether-cyclized helix B peptide, CHBP can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2. |
10-Hydroxy-2-decenoic acid
10-Hydroxy-2-decenoic acid (10-HDA) is the major lipid component of royal jelly produced by honeybees. |
mTOR inhibitor-11
mTOR inhibitor-11 is a brain-penetrant mTOR inhibitor (IC50: 21 nM for pS6). |
mTOR inhibitor-12
mTOR inhibitor-12 is a selective brain penetrant mTOR inhibitor without genotoxicity risk. |
Royleanone
Royleanone, a diterpenoid isolated from plants, inhibits the proliferation of cancer cells by inducing cell cycle arrest and mitochondria-mediated apoptosis. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.